| # | Title | Journal | Year | Citations |
|---|
| 1 | Alzheimer’s disease drug-development pipeline: few candidates, frequent failures | Alzheimer's Research and Therapy | 2014 | 1,398 |
| 2 | Recent global trends in the prevalence and incidence of dementia, and survival with dementia | Alzheimer's Research and Therapy | 2016 | 566 |
| 3 | Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease | Alzheimer's Research and Therapy | 2010 | 424 |
| 4 | Alzheimer’s disease prevention: from risk factors to early intervention | Alzheimer's Research and Therapy | 2017 | 424 |
| 5 | Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review | Alzheimer's Research and Therapy | 2015 | 419 |
| 6 | Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study | Alzheimer's Research and Therapy | 2012 | 402 |
| 7 | A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease | Alzheimer's Research and Therapy | 2017 | 396 |
| 8 | A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody | Alzheimer's Research and Therapy | 2021 | 380 |
| 9 | Immune phenotypes of microglia in human neurodegenerative disease: challenges to detecting microglial polarization in human brains | Alzheimer's Research and Therapy | 2015 | 376 |
| 10 | Immediate and long-term consequences of COVID-19 infections for the development of neurological disease | Alzheimer's Research and Therapy | 2020 | 367 |
| 11 | Dementia: a global health priority - highlights from an ADI and World Health Organization report | Alzheimer's Research and Therapy | 2012 | 357 |
| 12 | Plasma tau levels in Alzheimer's disease | Alzheimer's Research and Therapy | 2013 | 328 |
| 13 | Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease | Alzheimer's Research and Therapy | 2019 | 325 |
| 14 | Drug development in Alzheimer’s disease: the path to 2025 | Alzheimer's Research and Therapy | 2016 | 323 |
| 15 | BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease | Alzheimer's Research and Therapy | 2014 | 322 |
| 16 | On the path to 2025: understanding the Alzheimer’s disease continuum | Alzheimer's Research and Therapy | 2017 | 316 |
| 17 | Alpha-synuclein biology in Lewy body diseases | Alzheimer's Research and Therapy | 2014 | 288 |
| 18 | Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome | Alzheimer's Research and Therapy | 2013 | 286 |
| 19 | Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain | Alzheimer's Research and Therapy | 2017 | 285 |
| 20 | The gut microbiota-derived metabolite trimethylamine N-oxide is elevated in Alzheimer’s disease | Alzheimer's Research and Therapy | 2018 | 273 |
| 21 | Clinical subtypes of chronic traumatic encephalopathy: literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome | Alzheimer's Research and Therapy | 2014 | 257 |
| 22 | Alcohol use and dementia: a systematic scoping review | Alzheimer's Research and Therapy | 2019 | 244 |
| 23 | Truncated and modified amyloid-beta species | Alzheimer's Research and Therapy | 2014 | 233 |
| 24 | Prevalence of mixed pathologies in the aging brain | Alzheimer's Research and Therapy | 2014 | 232 |
| 25 | Aducanumab, gantenerumab, BAN2401, and ALZ-801—the first wave of amyloid-targeting drugs for Alzheimer’s disease with potential for near term approval | Alzheimer's Research and Therapy | 2020 | 218 |
| 26 | Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease | Alzheimer's Research and Therapy | 2018 | 216 |
| 27 | Amyloid β-protein oligomers and Alzheimer’s disease | Alzheimer's Research and Therapy | 2013 | 209 |
| 28 | Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials | Alzheimer's Research and Therapy | 2016 | 208 |
| 29 | Alcohol-related dementia: an update of the evidence | Alzheimer's Research and Therapy | 2013 | 199 |
| 30 | Role of neuroinflammation in neurodegeneration: new insights | Alzheimer's Research and Therapy | 2017 | 197 |
| 31 | Association between chronic periodontitis and the risk of Alzheimer’s disease: a retrospective, population-based, matched-cohort study | Alzheimer's Research and Therapy | 2017 | 197 |
| 32 | Chronic traumatic encephalopathy: a spectrum of neuropathological changes following repetitive brain trauma in athletes and military personnel | Alzheimer's Research and Therapy | 2014 | 195 |
| 33 | First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model | Alzheimer's Research and Therapy | 2014 | 193 |
| 34 | Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy | Alzheimer's Research and Therapy | 2010 | 189 |
| 35 | Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody | Alzheimer's Research and Therapy | 2016 | 185 |
| 36 | The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease | Alzheimer's Research and Therapy | 2020 | 183 |
| 37 | The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis | Alzheimer's Research and Therapy | 2014 | 181 |
| 38 | Mild traumatic brain injury: a risk factor for neurodegeneration | Alzheimer's Research and Therapy | 2010 | 175 |
| 39 | Evidence for impaired amyloid β clearance in Alzheimer's disease | Alzheimer's Research and Therapy | 2013 | 172 |
| 40 | Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease | Alzheimer's Research and Therapy | 2014 | 169 |
| 41 | The dynamics of monocytes and microglia in Alzheimer’s disease | Alzheimer's Research and Therapy | 2015 | 168 |
| 42 | Monoamine oxidase B is elevated in Alzheimer disease neurons, is associated with γ-secretase and regulates neuronal amyloid β-peptide levels | Alzheimer's Research and Therapy | 2017 | 164 |
| 43 | Neurons derived from sporadic Alzheimer’s disease iPSCs reveal elevated TAU hyperphosphorylation, increased amyloid levels, and GSK3B activation | Alzheimer's Research and Therapy | 2017 | 161 |
| 44 | Fyn kinase inhibition as a novel therapy for Alzheimer’s disease | Alzheimer's Research and Therapy | 2014 | 160 |
| 45 | Angiotensin-converting enzyme 2 is reduced in Alzheimer’s disease in association with increasing amyloid-β and tau pathology | Alzheimer's Research and Therapy | 2016 | 159 |
| 46 | A web-based normative calculator for the uniform data set (UDS) neuropsychological test battery | Alzheimer's Research and Therapy | 2011 | 156 |
| 47 | Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias | Alzheimer's Research and Therapy | 2014 | 156 |
| 48 | Cognitive training and cognitive rehabilitation for persons with mild to moderate dementia of the Alzheimer's or vascular type: a review | Alzheimer's Research and Therapy | 2013 | 154 |
| 49 | Aducanumab produced a clinically meaningful benefit in association with amyloid lowering | Alzheimer's Research and Therapy | 2021 | 152 |
| 50 | Is the risk of Alzheimer’s disease and dementia declining? | Alzheimer's Research and Therapy | 2015 | 151 |
